Announcements Trials

Browse Landscape

Phase

Phase NA 6 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2 Squamous Intraepithelial Lesions 1 Squamous Cell Carcinoma of Head and Neck 1 Skin Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Adenocarcinoma Locally Advanced 1 Neoplasm Metastasis 1 Melanoma 1 Kidney Neoplasms 1 Head and Neck Neoplasms 1 HIV Seropositivity 1 Gynecological Cancers 1 Colorectal Neoplasms 1 Colorectal Liver Metastases 1 Carcinoma, Hepatocellular 1

Interventions

Bevacizumab 69 Sorafenib 66 lenvatinib 59 durvalumab 38 sintilimab 33 Nivolumab 32 tislelizumab 28 atezolizumab 28 pembrolizumab 27 Oxaliplatin 26 tremelimumab 23 apatinib 22 Fluorouracil 22 Radiosurgery 20 regorafenib 19 camrelizumab 18 Doxorubicin 18 cabozantinib 16 Leucovorin 16 Capecitabine 16 Radiotherapy 14 Folfox protocol 14 donafenib 13 Gemcitabine 13 Cisplatin 12 toripalimab 11 Erlotinib Hydrochloride 10 Immune Checkpoint Inhibitors 9 spartalizumab 8 anlotinib 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Hepatocellular × Electroporation × Clear all

NCT03630640 2024-07-31

NIVOLEP

Assistance Publique - Hôpitaux de Paris

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡